Cytokinetics Incorporated logo

Cytokinetics IncorporatedNASDAQ: CYTK

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

30 April 2004

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$6.06 B
-46%vs. 3y high
90%vs. sector
-vs. 3y high
-vs. sector
-15%vs. 3y high
100%vs. sector
1.93 K
-15%vs. 3y high
99%vs. sector

Price

after hours | 12 min ago
$51.48-$0.34(-0.66%)

Dividend

No data over the past 3 years
$249.00 K$1.19 M
$249.00 K-$143.32 M

Analysts recommendations

Institutional Ownership

CYTK Latest News

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com04 November 2024 Sentiment: -

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 31, 2024 it granted stock options to purchase an aggregate of 17,712 shares of common stock and 11,499 restricted stock units (RSUs) that will be settled into shares of common stock upon vesting to 7 employees, whose employment commenced in October 2024, as a material inducement to their employment.

Cytokinetics Highlights Progress in Cardiac Myosin Modulation Programs and Global Commercial Launch Readiness at Investor & Analyst Day
globenewswire.com16 October 2024 Sentiment: POSITIVE

NDA for Aficamten Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil,  and AMBER-HFpEF, Phase 2 Clinical Trial of CK-586, Expected to Begin in Q4 Global Commercial Launch Preparations Underway for First  Potential Approval Towards Building Specialty Cardiovascular Franchise Company Recently Launched Unbranded Disease Awareness Campaign  “HCM Beyond The Heart” for Health Care Professionals SOUTH SAN FRANCISCO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) will provide an update on the company's cardiac myosin modulation programs and global commercial launch readiness for aficamten at its Investor and Analyst Day, “Heart Forward: Advancing Cardiac Myosin Modulation,” today at 8:30 AM Eastern Time in New York and streamed live online.

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com03 October 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 30, 2024 it granted stock options to purchase an aggregate of 88,653 shares of common stock and 57,558 restricted stock units (RSUs) that will be settled into shares of common stock upon vesting to 30 employees, whose employment commenced in September 2024, as a material inducement to their employment.

Cytokinetics Presents Additional Data From SEQUOIA-HCM at the HFSA Annual Scientific Meeting
globenewswire.com30 September 2024 Sentiment: POSITIVE

Responder Analyses Show Treatment with Aficamten Demonstrated Improvements on Multiple Assessments of Clinical Significance to Cardiologists

Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program
globenewswire.com24 September 2024 Sentiment: POSITIVE

Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases

Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study
benzinga.com09 September 2024 Sentiment: POSITIVE

Monday, Cytokinetics, Incorporated  CYTK announced that data from the Phase 1 study of CK-4021586 (CK-586) were presented in a poster session at the American College of Clinical Pharmacology Annual Meeting in Bethesda, MD.

Cytokinetics Announces Data From Phase 1 Study of CK-4021586
globenewswire.com09 September 2024 Sentiment: POSITIVE

Phase 2 Clinical Trial in Patients with Heart Failure  with Preserved Ejection Fraction Expected to Begin in Q4 2024

Cytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual Meeting
globenewswire.com05 September 2024 Sentiment: POSITIVE

Full Data from Phase 1 Study of CK-4021586 to be Presented on September 8, 2024 Full Data from Phase 1 Study of CK-4021586 to be Presented on September 8, 2024

Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024
globenewswire.com01 September 2024 Sentiment: POSITIVE

Data from Integrated Safety Analysis Across Three Clinical Trials Reinforces Robust Safety Profile of Aficamten

Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024
globenewswire.com01 September 2024 Sentiment: POSITIVE

Additional Data from SEQUOIA-HCM Demonstrate Favorable Cardiac Remodeling by Cardiac MRI, Improvements in Cardiac Structure and Function by Echocardiography, Symptom Relief and Improvement in Biomarkers with Aficamten

What type of business is Cytokinetics Incorporated?

Cytokinetics Inc. is a late-stage biopharmaceutical company. The company is focused on the discovery, development, and commercialization of first-in-class muscle activators as potential treatments for debilitating diseases where muscle performance is decreased and/or diminished. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and disorders. The company is developing small molecule drug candidates specifically designed to enhance muscle function and contractility. Cytokinetics, Inc. was founded in 1997, and its headquarters are located in South San Francisco, California.

What sector is Cytokinetics Incorporated in?

Cytokinetics Incorporated is in the Healthcare sector

What industry is Cytokinetics Incorporated in?

Cytokinetics Incorporated is in the Biotechnology industry

What country is Cytokinetics Incorporated from?

Cytokinetics Incorporated is headquartered in United States

When did Cytokinetics Incorporated go public?

Cytokinetics Incorporated initial public offering (IPO) was on 30 April 2004

What is Cytokinetics Incorporated website?

https://www.cytokinetics.com

Is Cytokinetics Incorporated in the S&P 500?

No, Cytokinetics Incorporated is not included in the S&P 500 index

Is Cytokinetics Incorporated in the NASDAQ 100?

No, Cytokinetics Incorporated is not included in the NASDAQ 100 index

Is Cytokinetics Incorporated in the Dow Jones?

No, Cytokinetics Incorporated is not included in the Dow Jones index

When was Cytokinetics Incorporated the previous earnings report?

No data

When does Cytokinetics Incorporated earnings report?

Next earnings report date is not announced yet